Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 42, Issue 1

Issues

Association between the CYP2C9 polymorphism and the drug metabolism phenotype

Elizabeta Topic / Mario Štefanovic / Marina Samardžija
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2004.014

Abstract

CYP2C9, an isoform of the cytochrome P450 enzyme, is involved in the metabolism of most of the drugs of choice for the treatment of thromboembolic disorders. Functional polymorphism is associated with two variant alleles (alleles *2 and *3) encoding CYP2C9 enzymes with a potentially different catalytic activity. The aim of the study was to determine the frequency of the CYP2C9 polymorphism in a representative sample of the Croatian population (n=177) and to assess the association between the CYP2C9 polymorphism and the warfarin dose in patients with thromboembolism (n=181). The CYP2C9 genotype was determined by polymerase chain reaction-restriction fragment length poymorphism (PCR-RFLP). According to the CYP2C9 genotype distribution, 31.2% of the healthy subjects were identified with a heterozygous or homozygous CYP2C9 variant genotype. The frequency of 2C9*2 and 2C9*3 alleles was 12.4% and 3.7%, respectively. There was no gender-related genotype or allele difference. In thromboembolism patients, the frequency of CYP2C9 alleles *2 and *3 was 17.4% and 6.6%, respectively, and did not differ significantly from the control group. Almost half (42.5%) of the patients carried at least one variant CYP2C9 genotype. The allele difference between patient subgroups receiving warfarin doses lower and higher than the optimal warfarin dose (4.1 mg/day) was significant (p=0.027), especially for allele 2C9*3 (p=0.019; OR 3.250, 95%, CI 1.263–8.413). Comparison of the warfarin dose between patients with different genotypes yielded a significant dose difference between the patients with wild-type genotype and those with variant genotypes (Kruskall-Wallis, χ2=9.745, p=0.008). The results of the association of each of five genotype combinations with the warfarin maintenance dose revealed it to be significantly related to the genotype (Kruskall-Wallis, χ2=12.854, p=0.025). Expressed as percentage of the mean dose in patients with wild-type alleles, the mean warfarin maintenance dose was 92% in 2C9*2 heterozygotes, 74% in 2C*3 heterozygotes, 61% in 2C9*2 homozygotes, 34% in 2C9*3 homozygotes and 63% in compound heterozygotes for 2C9*2 and 2C9*3. Although the mean maintenance dose in homozygous *2/*2 and compound *2/*3 genotype patients was markedly lower (mean 2.66 mg and 2.75 mg, respectively, vs. 4.37 mg), statistical analysis yielded no significance because of the small number of patients carrying these genotypes. A significantly lower maintenance dose was observed in the subgroup of heterozygous *1/*3 genotype patients (p=0.022). These preliminary results suggest a significant association of the CYP2C9 polymorphism with the warfarin dose and underline the importance of pre-therapeutic genotyping to identify the subjects likely to develop undesirable drug effects.

About the article

Published Online: 2005-06-01

Published in Print: 2004-02-16


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 42, Issue 1, Pages 72–78, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2004.014.

Export Citation

Copyright © 2004 by Walter de Gruyter GmbH & Co. KG.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Li Hua Jin, Bo-Hyung Kim, Ji Hyun Lee, Kidong Lee, KyuBum Kwack, and Sung-Vin Yim
Translational and Clinical Pharmacology, 2017, Volume 25, Number 4, Page 166
[2]
Silvia Vogl, Roman W. Lutz, Gilbert Schönfelder, Werner K. Lutz, and Noam Shomron
PLOS ONE, 2015, Volume 10, Number 3, Page e0120403
[3]
Jie Yang, Yanming Chen, Xiaoqi Li, Xiaowen Wei, Xi Chen, Lanning Zhang, Yuxiao Zhang, Qiang Xu, Hongjuan Wang, Yang Li, Caiyi Lu, Wei Chen, Changqing Zeng, and Tong Yin
International Journal of Cardiology, 2013, Volume 168, Number 4, Page 4234
[4]
Elena García-Martín, Carmen Martínez, José M. Ladero, and José A. G. Agúndez
Molecular Diagnosis & Therapy, 2006, Volume 10, Number 1, Page 29
[5]
Monica R McClain, Glenn E Palomaki, Margaret Piper, and James E Haddow
Genetics in Medicine, 2008, Volume 10, Number 2, Page 89
[6]
Hajime NAKASHIMA, Jun MIURA, Tsukasa UNO, Terufumi MATSUNAGA, and Tomonori TATEISHI
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, Volume 42, Number 5, Page 333
[7]
B.J. Anderson and G.M. Palmer
Biomedicine & Pharmacotherapy, 2006, Volume 60, Number 7, Page 303
[8]
Pramod Mahajan, Kristin S. Meyer, Geoffrey C. Wall, and Heidi J. Price
International Journal of Clinical Pharmacy, 2011, Volume 33, Number 1, Page 10
[9]
Giuseppe Lippi, Massimo Franchini, and Emmanuel J. Favaloro
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 5
[10]
Ligia Chialda, Lee S Griffith, Antoinette Heinig, and Andreas Pahl
Personalized Medicine, 2008, Volume 5, Number 1, Page 37
[11]
Alisara Sangviroon, Duangchit Panomvana, Wichittra Tassaneeyakul, and Jule Namchaisiri
Drug Metabolism and Pharmacokinetics, 2010, Volume 25, Number 6, Page 531
[12]
Pramod Mahajan, Kristin S. Meyer, Geoffrey C. Wall, and Heidi J. Price
International Journal of Clinical Pharmacy, 2013, Volume 35, Number 3, Page 359
[13]
H Xu, K M Williams, W S Liauw, M Murray, R O Day, and A J McLachlan
British Journal of Pharmacology, 2009, Volume 153, Number 7, Page 1579
[14]
Julio César Rojas, Bernardo Aguilar, Emma Rodríguez-Maldonado, and María Teresa Collados
Blood Coagulation & Fibrinolysis, 2005, Volume 16, Number 6, Page 389
[15]
Jonatan D. Lindh, Lennart Holm, Marine L. Andersson, and Anders Rane
European Journal of Clinical Pharmacology, 2009, Volume 65, Number 4, Page 365
[16]
Brian J. Anderson and Greta M. Palmer
Current Opinion in Anaesthesiology, 2006, Volume 19, Number 3, Page 285
[17]
Miriam del Carmen Carrasco-Portugal, Jos?? Carlos Aguilar-Carrasco, Miguel Luj??n, Gerardo Reyes-Garc??a, Roberto Medina-Santill??n, and Francisco J Flores-Murrieta
Clinical Drug Investigation, 2005, Volume 25, Number 5, Page 307

Comments (0)

Please log in or register to comment.
Log in